

Special Issue

PD-1/PD-L1 Immune Checkpoint Therapy: From Predictive Biomarkers to Noninvasive Imaging

Message from the Guest Editors

This Special Issue will focus on recent advances in the efficacy/safety profile of PD-1/PD-L1 blockade in cancer treatment, from biomarker-driven therapy to novel radiopharmaceuticals (immuno-PET radiotracers) and drug combinations. Evidence on the role of optimized combination detection markers to further improve the accuracy of PD-L1 in predicting the efficacy of PD-1/PD-L1 blockades and the application of artificial intelligence techniques in the field of personalized immunotherapy will be also welcomed.

Guest Editors

Prof. Dr. Patrizia Ferroni

Prof. Dr. Fiorella Guadagni

Prof. Dr. Mario Roselli

Deadline for manuscript submissions

closed (25 April 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/139017

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)